BackenVVeno Medical - Warrants (30/05/2023) Overview
enVVeno Medical Corporation - Warrants (30/05/2023)

enVVeno Medical - Warrants (30/05/2023) Return on Equity

Latest ROE for enVVeno Medical - Warrants (30/05/2023): -76.07% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-76.07%

Return on Equity

-76.07%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

enVVeno Medical - Warrants (30/05/2023) (NVNOW) FAQ

enVVeno Medical - Warrants (30/05/2023)'s return on equity stands at -76.07%. That is below the Healthcare sector average of 20.86%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

enVVeno Medical - Warrants (30/05/2023) sits lower the Healthcare benchmark (20.86%) with a ROE of -76.07%. That is roughly 464.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -76.07% for enVVeno Medical - Warrants (30/05/2023) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how enVVeno Medical - Warrants (30/05/2023)'s ROE evolved across reporting periods, while the comparison chart places NVNOW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. enVVeno Medical - Warrants (30/05/2023)'s reading of -76.07% (sector avg 20.86%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.